Clinical connexions

Journal of Clinical Pathology

Volumn 61, Issue 8, 2008, Pages 885-890

  Alldredge, Brett ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNEXIN 26; CONNEXIN 30; CONNEXIN 31; CONNEXIN 32; CONNEXIN 36; CONNEXIN 37; CONNEXIN 40; CONNEXIN 43; CONNEXIN 45; CONNEXIN 47; GAP JUNCTION PROTEIN;

ALCOHOLISM; ALZHEIMER DISEASE; BIOPHYSICS; BRAIN DAMAGE; BRAIN ISCHEMIA; CARCINOGENICITY; CATARACT; CELL ADHESION; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; CEREBROVASCULAR ACCIDENT; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CORPUS CAVERNOSUM; DRUG DEPENDENCE; ELECTROSTIMULATION; EPIDIDYMIS; EPILEPSY; EPILEPTOGENESIS; FEMALE GENITAL SYSTEM; FEMALE INFERTILITY; GAP JUNCTION; GENE MUTATION; GENETIC POLYMORPHISM; HEARING IMPAIRMENT; HEARING LOSS; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART INFARCTION; HEREDITARY MOTOR SENSORY NEUROPATHY; HETEROTAXY SYNDROME; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; HYPOPLASTIC LEFT HEART SYNDROME; ICHTHYOSIS; INSULIN RELEASE; KERATITIS; KERATODERMA HEREDITARIUM MUTILANS; MEDICAL RESEARCH; MONOCYTE; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; OCULODENTODIGITAL SYNDROME; OVARY FOLLICLE DEVELOPMENT; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PELIZAEUS MERZBACHER DISEASE; PENIS ERECTION; PLACENTA; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOMA; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SEMINAL VESICLE; SEMINOMA; SPERMATOGENESIS; STEROIDOGENESIS; SYNAPSE; TESTIS;

CARDIOVASCULAR DISEASES; CONNEXINS; GAP JUNCTIONS; HOMEOSTASIS; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; SKIN DISEASES;

EID: 49149089951     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2008.055699     Document Type: Review

References (138)

1. Harris AL. Emerging issues of connexin channels: biophysics fills the gap. Q Rev Biophys 2001;34:325-472.
2. Willecke K, Eiberger J, Degen J, et al. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 2002;383:725-37.
3. Barr L, Berger W, Dewey MM. Electrical transmission at the nexus between smooth muscle cells. J Gen Physiol 1968;51:347-68.
4. Lagaud G, Davies KP, Venkateswarlu K, et al. The physiology, pathophysiology and therapeutic potential of gap junctions in smooth muscle. Curr Drug Targets 2002;3:427-40.
5. Michon L, Nlend R, Bavamian S, et al. Involvement of gap junctional communication in secretion. Biochim Biophys Acta 2005;1719:82-101.
6. Serre-Beinier V, Mas C, Calabrese A, et al. Connexins and secretion. Biol Cell 2002;94:477-92.
7. Connors BW, Long MA. Electrical synapses in the mammalian brain. Annu Rev Neurosci 2004;27:393-418.
8. Hormuzdia G, Filippova MA, Mitropouloub G, et al. Electrical synapses: a dynamic signaling system that shapes the activity of neuronal networks. Biochim Biophys Acta 2004;1662:113-37.
9. Long MA, Landisman CE, Connors BW. Small clusters of electrically coupled neurons generate synchronous rhythms in the thalamic reticular nucleus. J Neurosci 2004;24:341-9.
10. Spray DC, Iacobas DA. Organizational principles of the connexin-related brain transcriptome. J Membr Biol 2007:218:39-47.
11. Spray DC, Rozental R, Srinivas M. Prospects for rational development of pharmacological gap junction channel blockers. Curr Drug Targets 2002;3:455-64.
12. Salameh A, Dhein S. Pharmacology of gap junctions: new pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim Biophys Acta 2005;1719:36-58.
13. Hervé JC, Sarrouilhe D. Connexin-made channels as pharmacological targets. Curr Pharm Des 2005;11:1941-58.
14. Richard G. Connexin disorders of the skin. Clin Dermatol 2005;23:23-32.
15. Meşe G, Richard G, White TW. Gap junctions: basic structure and function. J Invest Dermatol 2007;127:2516-24.
16. Mazereeuw-Hautier J, Bitoun E, Chevrant-Breton J, et al. Keratitis-ichthyosis-deafness syndrome: disease expression and spectrum of connexin 26 (GJB2) mutations in 14 patients. Br J Dermatol 2007;156:1015-9.
17. van Geel M, van Steensel MA, Küster W, et al. HID and KID syndromes are associated with the same connexin 26 mutation. Br J Dermatol 2002;146:938-42.
18. Richard G, Smith LE, Bailey RA, et al. Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat Genet 1998;20:366-9.
19. Richard G, Brown N, Rouan F, et al. Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. J Invest Dermatol 2003;120:601-9.
20. Macari F, Landau M, Cousin P, et al. Mutation in the gene for connexin 30.3 in a family with erythrokeratodermia variabilis. Am J Hum Genet 2000;67:1296-301.
21. Bondeson ML, Nyström AM, Gunnarsson U, et al. Connexin 26 (GJB2) mutations in two Swedish patients with atypical Vohwinkel (mutilating keratoderma plus deafness) and KID syndrome both extensively treated with acitretin. Acta Derm Venereol 2006;86:503-8.
22. Zhang X, Ren Z, Zuo J, et al. The effect of all-trans retinoic acid on gap junctional intercellular communication and connexin 43 gene expression in glioma cells. Chin Med Sci J 2002;17:22-6.
23. Carystinos GD, Alaoui-Jamali MA, Phipps J, et al. Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-transretinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. Cancer Chemother Pharmacol 2001;47:126-32.
24. Ara C, Massimi M, Devirgiliis Conti L. Retinoic acid modulates gap junctional intercellular communication in hepatocytes and hepatoma cells. Cell Mol Life Sci 2002;59:1758-65.
25. Coutinho P, Qiu C, Frank S, et al. Dynamic changes in connexin expression correlate with key events in the wound healing process. Cell Biol Int 2003;27:525-41.
26. Goliger JA, Paul DL. Wounding alters epidermal connexin expression and gap junction-mediated intercellular communication. Mol Biol Cell 1995;6:1491-501.
27. Kretz M, Euwens C, Hombach S, et al. Altered connexin expression and wound healing in the epidermis of connexin-deficient mice. J Cell Sci 2003;116:3443-52.
28. Qiu C, Coutinho P, Frank S, et al. Targeting connexin43 expression accelerates the rate of wound repair. Curr Biol 2003;13:1697-703.
29. Mori R, Power KT, Wang CM, et al. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci 2006;119:5193-203.
30. Coutinho P, Qiu C, Frank S, et al. Limiting burn extension by transient inhibition of Connexin43 expression at the site of injury. Br J Plast Surg 2005;58:658-67.
31. Djalilian AR, McGaughey D, Patel S, et al. Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J Clin Invest 2006;116:1243-53.
32. Djalilian AR, McGaughey D, Patel S, et al. Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J Clin Invest 2006;116:1243-53.
33. Mesnil M. Connexins and cancer. Biol Cell 2002;94:493-500.
34. Pointis G, Fiorini C, Gilleron J, et al. Connexins as precocious markers and molecular targets for chemical and pharmacological agents in carcinogenesis. Curr Med Chem 2007;14:2288-303.
35. Trosko JE. The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed Pharmacother 2005;59:326-31.
36. Mesnil M, Crespin S, Avanzo JL, et al. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005:1719:125-45.
37. Pointis G, Fiorini C, Defamie N, et al. Gap junctional communication in the male reproductive system. Biochim Biophys Acta 2005;1719:102-16.
38. Pointis G, Segretain D. Role of connexin-based gap junction channels in testis. Trends Endocrinol Metab 2005;16:300-6.
39. Pointis G. Connexin43: emerging role in erectile function. Int J Biochem Cell Biol 2006;38:1642-6.
40. Kidder GM, Mhawi AA. Gap junctions and ovarian folliculogenesis. Reproduction 2002;123:613-20.
41. Webb RJ, Bains H, Cruttwell C, et al. Gap-junctional communication in mouse cumulus-oocyte complexes: implications for the mechanism of meiotic maturation. Reproduction 2002;123:41-52.
42. Gittens JE, Mhawi AA, Lidington D, et al. Functional analysis of gap junctions in ovarian granulosa cells: distinct role for connexin43 in early stages of folliculogenesis. Am J Physiol Cell Physiol 2003;284:C880-7.
43. Simon AM, Goodenough DA, Li E, et al. Female infertility in mice lacking connexin 37. Nature 1997;385:525-9.
44. Borowczyk E, Johnson ML, Bilski JJ, et al. Role of gap junctions in regulation of progesterone secretion by ovine luteal cells in vitro. Reproduction 2007:133:641-51.
45. Döring B, Shynlova O, Tsui P, et al. Ablation of connexin43 in uterine smooth muscle cells of the mouse causes delayed parturition. J Cell Sci 2006;119:1715-22.
46. Malassiné A, Cronier L. Involvement of gap junctions in placental functions and development. Biochim Biophys Acta 2005;1719:117-24.
47. Duffy HS, Fort AG, Spray DC. Cardiac connexins: genes to nexus. Adv Cardiol 2006;42:1-17.
48. Severs NJ, Dupont E, Thomas N, et al. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol 2006;42:228-42.
49. Severs NJ, Dupont E, Coppen SR, et al. Remodelling of gap junctions and connexin expression in heart disease. Biochim Biophys Acta 2004;1662:138-48.
50. Britz-Cunningham SH, Shah MM, Zuppan CW, et al. Mutations of the connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med 1995;332:1323-9.
51. Dasgupta C, Martinez AM, Zuppan CW, et al. Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat Res 2001;479:173-86.
52. Gollob MH. Cardiac connexins as candidate genes for idiopathic atrial fibrillation. Curr Opin Cardiol 2006;21:155-8.
53. Kirchhoff S, Nelles E, Hagendorff A, et al. Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol 1998:8:299-302.
54. Figueroa XF, Isakson BE, Duling BR. Connexins: gaps in our knowledge of vascular function. Physiology 2004;19:277-84.
55. Christ GJ, Spray DC, el-Sabban M, et al. Gap junctions in vascular tissues. Evaluating the role of intercellular communication in the modulation of vasomotor tone. Circ Res 1996;79:631-46.
56. Chadjichristos CE, Derouette JP, Kwak BR. Connexins in atherosclerosis. Adv Cardiol 2006;42:255-67.
57. Wong CW, Christen T, Roth I, et al. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med 2006;12:950-4.
58. Kwak BR, Pepper MS, Gros DB, et al. Inhibition of endothelial wound repair by dominant negative connexin inhibitors. Mol Biol Cell 2001;12:831-45.
59. Haefliger JA, Nicod P, Meda P. Contribution of connexins to the function of the vascular wall. Cardiovasc Res 2004;62:345-56.
60. de Wit C, Roos F, Bolz SS, et al. Lack of vascular connexin 40 is associated with hypertension and irregular arteriolar vasomotion. Physiol Genomics 2003;13:169-77.
61. de Wit C, Roos F, Bolz SS, et al. Impaired conduction of vasodilation along arterioles in connexin40-deficient mice. Circ Res 2000;86:649-55.
62. Liao Y, Day KH, Damon DN, et al. Endothelial cell-specific knockout of connexin 43 causes hypotension and bradycardia in mice. Proc Natl Acad Sci U S A 2001;98:9989-94.
63. Firouzi M, Kok B, Spiering W, et al. Polymorphisms in human connexin40 gene promoter are associated with increased risk of hypertension in men. J Hypertens 2006;24:325-30.
64. Wong CW, Christen T, Pfenniger A, et al. Do allelic variants of the connexin37 1019 gene polymorphism differentially predict for coronary artery disease and myocardial infarction? Atherosclerosis 2007;191:355-61.
65. Chen X, Zhang Y. Myocardial Cx43 expression in the cases of sudden death due to dilated cardiomyopathy. Forensic Sci Int 2006;162:170-3.
66. Dhein S. Pharmacology of gap junctions in the cardiovascular system. Cardiovasc Res 2004;62:287-98.
67. Hervé JC, Dhein S. Pharmacology of cardiovascular gap junctions. Adv Cardiol 2006;42:107-31.
68. Söhl G, Maxeiner S, Willecke K. Expression and functions of neuronal gap junctions. Nat Rev Neurosci 2005;6:191-200.
69. Carlen PL, Skinner F, Zhang L, et al. The role of gap junctions in seizures. Brain Res Brain Res Rev 2000;32:235-41.
70. Nemani VM, Binder DK. Emerging role of gap junctions in epilepsy. Histol Histopathol 2005;20:253-9.
71. Lee SH, Magge S, Spencer DD, et al. Human epileptic astrocytes exhibit increased gap junction coupling. Glia 1995;15:195-202.
72. Nilsen KE, Kelso AR, Cock HR. Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. Epilepsia 2006;47:1169-75.
73. Gigout S, Louvel J, Pumain R. Effects in vitro and in vivo of a gap junction blocker on epileptiform activities in a genetic model of absence epilepsy. Epilepsy Res 2006;69:15-29.
74. Gajda Z, Szupera Z, Blazsó G, et al. Quinine, a blocker of neuronal Cx36 channels, suppresses seizure activity in rat neocortex in vivo. Epilepsia 2005;46:1581-91.
75. Cruikshank SJ, Hopperstad M, Younger M, et al. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci USA 2004;101:12364-9.
76. Martin FC, Handforth A. Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor. Mov Disord 2006;21:1641-9.
77. Mas C, Taske N, Deutsch S, et al. Association of the connexin36 gene with juvenile myoclonic epilepsy. J Med Genet 2004;41:e93.
78. de Pina-Benabou MH, Szostak V, Kyrozis A, et al. Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke 2005;36:2232-7.
79. Rawanduzy A, Hansen A, Hansen TW, et al. Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke. J Neurosurg 1997;87:916-20.
80. Rami A, Volkmann T, Winckler J. Effective reduction of neuronal death by inhibiting gap junctional intercellular communication in a rodent model of global transient cerebral ischemia. Exp Neurol 2001;170:297- 304.
81. Nakase T, Yoshida Y, Nagata K. Enhanced connexin 43 immunoreactivity in penumbral areas in the human brain following ischemia. Glia 2006;54:369-75.
82. Omori Y, Mesnil M, Yamasaki H. Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects. Mol Biol Cell 1996;7:907-16.
83. Ressot C, Gomès D, Dautigny A, et al. Connexin32 mutations associated with X-linked Charcot-Marie-Tooth disease show two distinct behaviors: loss of function and altered gating properties. J Neurosci 1998;18:4063-75.
84. Abrams CK, Oh S, Ri Y, et al. Mutations in connexin 32: the molecular and biophysical bases for the X-linked form of Charcot-Marie-Tooth disease. Brain Res Brain Res Rev 2000;32:203-14.
85. Ikegami T, Lin C, Kato M, et al. Four novel mutations of the connexin 32 gene in four Japanese families with Charcot-Marie-Tooth disease type 1. Am J Med Genet 1998;80:352-5.
86. Roscoe WA, Messersmith E, Meyer-Franke A, et al. Connexin 43 gap junction proteins are up-regulated in remyelinating spinal cord. Neurosci Res 2007;85:945-53.
87. Brand-Schieber E, Werner P, Iacobas DA, et al. Connexin43, the major gap junction protein of astrocytes, is down-regulated in inflamed white matter in an animal model of multiple sclerosis. J Neurosci Res 2005;80:798-808.
88. Paznekas WA, Boyadjiev SA, Shapiro RE, et al. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am J Hum Genet 2003;72:408-18.
89. Uhlenberg B, Schuelke M, Rüschendorf F, et al. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet 2004;75:251-60.
90. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004;5:483-94.
91. Allison DW, Ohran AJ, Stobbs SH, et al. Connexin-36 gap junctions mediate electrical coupling between ventral tegmental area GABA neurons. Synapse 2006;60:20-31.
92. McCracken CB, Hamby SM, Patel KM, et al. Extended cocaine self-administration and deprivation produces region-specific and time-dependent changes in connexin36 expression in rat brain. Synapse 2005;58:141-50.
93. Bennett SA, Arnold JM, Chen J, et al. Long-term changes in connexin32 gap junction protein and mRNA expression following cocaine self-administration in rats. Eur J Neurosci 1999;11:3329-38.
94. McCracken CB, Patel KM, Vrana KE, et al. Amphetamine withdrawal produces region-specific and time-dependent changes in connexin36 expression in rat brain. Synapse 2005;56:39-44.
95. John ER, Prichep LS. The anesthetic cascade: a theory of how anesthesia suppresses consciousness. Anesthesiology 2005;102:447- 71.
96. Villars PS, Kanusky JT, Dougherty TB. Stunning the neural nexus: mechanisms of general anesthesia. AANA J 2004;72:197-205.
97. Hemmings HC, Akabas MH, Goldstein PA, et al. Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci 2005;26:503-10.
98. Dilger JP. The effects of general anaesthetics on ligand-gated ion channels. Br J Anaesth 2002;89:41-51.
99. Johansson JS. Central nervous system electrical synapses as likely targets for intravenous general anesthetics. Anesth Analg 2006;102:1689-91.
100. Wentlandt K, Carlen PL, Kushnir M, et al. General anesthetics attenuate gap junction coupling in P19 cell line. J Neurosci Res 2005;81:746-52.
101. Wentlandt K, Samoilova M, Carlen PL, et al. General anesthetics inhibit gap junction communication in cultured organotypic hippocampal slices. Anesth Analg 2006;102:1692-8.
102. Masaki E, Kawamura M, Kato F. Attenuation of gap-junction-mediated signaling facilitated anesthetic effect of sevoflurane in the central nervous system of rats. Anesth Analg 2004;98:647-52.
103. Goadsby PJ. Emerging therapies for migraine. Nat Clin Pract Neurol 2007;3:610-9.
104. Grafstein B, Liu S, Cotrina ML, et al. Meningeal cells can communicate with astrocytes by calcium signaling. Ann Neurol. 2000;47:18-25.
105. Meyer J, Mai M, Ortega G, et al. Mutational analysis of the connexin 36 gene (CX36) and exclusion of the coding sequence as a candidate region for catatonic schizophrenia in a large pedigree. Schizophr Res 2002;58:87-91.
106. Aleksic B, Ishihara R, Takahashi N, et al. Gap junction coding genes and schizophrenia: a genetic association study. J Hum Genet 2007;52:498-501.
107. Nagy JI, Li W, Hertzberg EL, et al. Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer's disease. Brain Res 1996;717:173-8.
108. Vis JC, Nicholson LF, Faull RL, et al. Connexin expression in Huntington's diseased human brain. Cell Biol Int 1998;22:837- 47.
109. Rufer M, Wirth SB, Hofer A, et al. Regulation of connexin-43, GFAP, and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-lesioned, FGF-2-treated parkinsonian mice. J Neurosci Res 1996;46:606-17.
110. Serre-Beinier V, Le Gurun S, Belluardo N, et al. Cx36 preferentially connects beta-cells within pancreatic islets. Diabetes 2000;49:727-34.
111. Moreno AP, Berthoud VM, Pérez-Palacios G, et al. Biophysical evidence that connexin-36 forms functional gap junction channels between pancreatic mouse beta-cells. Am J Physiol Endocrinol Metab 2005;288:E948-56.
112. 2+ and insulin oscillations, and basal insulin release. Diabetes 2005;54:1798-807.
113. Nlend RN, Michon L, Bavamian S, et al. Connexin36 and pancreatic beta-cell functions. Arch Physiol Biochem 2006;112:74- 81.
114. Klee P, Charollais A, Caille D, et al. Connexin modulators of endocrine function. In: Winterhager E, ed. Gap junctions in development and disease. New York: Springer-Verlag, 2005.
115. Murray SA, Oyoyo UA, Pharrams SY, et al. Characterization of gap junction expression in the adrenal gland. Endocr Res 1995;21:221-9.
116. Murray SA, Davis K, Gay V. ACTH and adrenocortical gap junctions. Microsc Res Tech 2003;61:240-6.
117. Shah US, Murray SA. Bimodal inhibition of connexin 43 gap junctions decreases ACTH-induced steroidogenesis and increases bovine adrenal cell population growth. J Endocrinol 2001;171:199-208.
118. Al-Ubaidi MR, White TW, Ripps H, et al. Functional properties, developmental regulation, and chromosomal localization of murine connexin36, a gap-junctional protein expressed preferentially in retina and brain. J Neurosci Res 2000;59:813-26.
119. Massey SC, O'Brien JJ, Trexler EB, et al. Multiple neuronal connexins in the mammalian retina. Cell Commun Adhes 2003;10:425-30.
120. O'Brien JJ, Li W, Pan F, et al. Coupling between A-type horizontal cells is mediated by connexin 50 gap junctions in the rabbit retina. J Neurosci 2006;26:11624-36.
121. Deans MR, Volgyi B, Goodenough DA, et al. Connexin36 is essential for transmission of rod-mediated visual signals in the mammalian retina. Neuron 2002;36:703-12.
122. Güldenagel M, Ammermüller J, Feigenspan A, et al. Visual transmission deficits in mice with targeted disruption of the gap junction gene connexin36. J Neurosci 2001;21:6036-44.
123. Bennett TM, Mackay DS, Knopf HL, et al. A novel missense mutation in the gene for gap-junction protein alpha3 (GJA3) associated with autosomal dominant "nuclear punctuate" cataracts linked to chromosome 13q. Mol Vis 2004;10:376-82.
124. Mackay D, Ionides A, Kibar Z, et al. Connexin46 mutations in autosomal dominant congenital cataract. Am J Hum Genet 1999;64:1357-64.
125. Pal JD, Berthoud VM, Beyer EC, et al. Molecular mechanism underlying a Cx50-linked congenital cataract. Am J Physiol 1999;276:C1443-6.
126. Gerido DA, White TW. Connexin disorders of the ear, skin, and lens. Biochim Biophys Acta 2004;1662:159-70.
127. Apps SA, Rankin WA, Kurmis AP. Connexin 26 mutations in autosomal recessive deafness disorders: a review. Int J Audiol 2007;46:75- 81.
128. Feng Y, He C, Xia K, et al. Mutation analysis of gene CX31.1 in the hereditary hearing loss pedigrees. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2005;19:178-9.
129. Meşe G, Londin E, Mui R, et al. Altered gating properties of functional Cx26 mutants associated with recessive non-syndromic hearing loss. Hum Genet 2004;115:191-9.
130. Kikuchi T, Adams JC, Miyabe Y, et al. Potassium ion recycling pathway via gap junction systems in the mammalian cochlea and its interruption in hereditary nonsyndromic deafness. Med Electron Microsc 2000;33:51-6.
131. Ahmad S, Tang W, Chang Q, et al. Restoration of connexin26 protein level in the cochlea completely rescues hearing in a mouse model of human connexin30-linked deafness. Proc Natl Acad Sci USA 2007;104:1337-41.
132. Oviedo-Orta E, Howard Evans W. Gap junctions and connexin-mediated communication in the immune system. Biochim Biophys Acta 2004;1662:102-12.
133. Chanson M, Berclaz PY, Scerri I, et al. Regulation of gap junctional communication by a pro-inflammatory cytokine in cystic fibrosis transmembrane conductance regulator-expressing but not cystic fibrosis airway cells. Am J Pathol 2001;158:1775-84.
134. Neuhaus J, Pfeiffer F, Wolburg H, et al. Alterations in connexin expression in the bladder of patients with urge symptoms. BJU Int 2005;96:670-6.
135. Wang YF, Daniel EE. Gap junctions in gastrointestinal muscle contain multiple connexins. Am J Physiol Gastrointest Liver Physiol 2001;281:G533-43.
136. Takayama I, Horiguchi K, Daigo Y, et al. The interstitial cells of Cajal and a gastroenteric pacemaker system. Arch Histol Cytol 2002;65:1-26.
137. Nemeth L, Maddur S, Puri P. Immunolocalization of the gap junction protein Connexin43 in the interstitial cells of Cajal in the normal and Hirschsprung's disease bowel. Pediatr Surg 2000;35:823-8.
138. Ilvesaro J, Tuukkanen J. Gap-junctional regulation of osteoclast function. Crit Rev Eukaryot Gene Expr 2003;13:133-46.